Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)

NCT07923747 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07923747 Not yet recruiting Phase 1 90 participants (estimated) Started 2026

Follow this trial by email Email me the PDF

Get the NCT07923747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, Phase 1, 90 participants (estimated). Lead sponsor Novartis Pharmaceuticals. Primary measure: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).

How it compares

267 similar trials: same condition (Lupus Erythematosus, Systemic) and phase

Enrollment

This trial
90
Middle half
12 to 48
Median
23
Trials with a value
267

Months from start to completion

This trial
26.7
Middle half
17 to 39.1
Median
29
Trials with a value
264

Sites

This trial
Not reported
Middle half
1 to 6
Median
1
Trials with a value
246
Posted results or a linked paper 25% 68 of 267 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Official title
A Two-part, First-In-Human, Phase I, Open-label, Ascending Dose Study to Assess Safety and Tolerability of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
February 21, 2029
Enrollment
90 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Arthritis, Rheumatoid, Lupus Erythematosus, Systemic

Registry terms: rheumatoid arthritis and systemic lupus erythematosus

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
Novartis Pharmaceuticals

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Part A- Cohort A-DKB903 Experimental DKB903
Show registry wording

Participants will receive DKB903 at escalating dose levels.

Part B- Cohort B-DKB903 dose level identified as safe in Part A Experimental DKB903
Show registry wording

DKB903 dose level identified as safe in Part A, plus up to two additional full doses.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) From Day 1 up to approximately 2 years.
Show registry wording

Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

Lead sponsor's other trials

Novartis Pharmaceuticals, most recent start first.

Similar trials

Same condition (Lupus Erythematosus, Systemic) and phase, most recent start first.